Bifurcation Lesions Market Size To Reach $3.5 Billion By 2030

Bifurcation Lesions Market Growth & Trends

The global bifurcation lesions market size is expected to reach USD 3.5 billion by 2030, registering a CAGR of 6.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Technological developments and supportive government initiatives for reimbursement are likely to drive the market during the forecast period.

The increasing geriatric population and unhealthy lifestyle are responsible for growth in the incidence of cardiovascular disorders. Furthermore, an increase in approval & commercialization of innovative devices and the expected entry of new devices for the treatment of bifurcation lesions in the coming years are likely to drive the market.

In addition, factors such as rising affordability, increase in demand for minimally invasive procedures, and growing medical tourism are also boosting demand for bifurcation lesions procedures across the globe. According to various studies, procedures for coronary bifurcation lesions comprise approximately 20% of total percutaneous coronary interventions.

 Request a free sample copy or view report summary: Bifurcation Lesions Market Report

Bifurcation Lesions Market Report Highlights

• Increase in the commercialization of devices for bifurcation lesions and investments by industry players for R&D are the factors expected to boost the market, resulting in an anticipated CAGR of around 6.0% from 2025 to 2030

• The coronary vascular segment accounted for the maximum share of the market in 2024 due to the presence of complex vascular network in heart, increased availability of devices, and rise in awareness regarding surgical interventions for bifurcation lesions.

• The peripheral vascular segment is likely to witness lucrative growth in the coming years due to an increase in investments by industry players for the development of devices for peripheral application and advancements in diagnostics facilitating accurate detection of plaque.

• Geographically, North America held the largest share of the bifurcation lesions market in 2024. It is anticipated to maintain its dominance in the coming years due to increasing demand for drug-eluting stents, commercialization of devices for bifurcation lesions, and the local presence of major market players.

• The Asia Pacific is expected to observe the fastest growth over the next decade owing to improvement in healthcare infrastructure, medical tourism, and a rise in investments by market players in the region.

• Some of the key players in the market are Abbott; Boston Scientific Corporation; Cardinal Health; Medtronic; Johnson & Johnson Services, Inc.; C. R. Bard, Inc.; Spectranetics; and Terumo Medical Corporation. Tryton Medical, Inc. developed the Tryton Side Branch Stent with a balloon-expandable, single-wire stent delivery system that can be deployed in the side branch artery for treatment of bifurcation lesions. The device is available in the U.S. and Europe as well as Middle East & Africa.

Bifurcation Lesions Market Segmentation

Grand View Research has segmented the global bifurcation lesions market report based on application and region

Bifurcation Lesions Application Outlook (Revenue, USD Million, 2018 - 2030)

• Coronary

• Peripheral

Bifurcation Lesions Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

• U.S.

• Canada

• Mexico

• Europe

• UK

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

• Asia Pacific

• Japan

• China

• India

• South Korea

• Australia

• Thailand

• Latin America

• Brazil

• Argentina

• Middle East & Africa

• South Africa

• Saudi Arabia

• UAE

• Kuwait

List of Key Players of Bifurcation Lesions Market

• Boston Scientific Corp.

• Abbott

• Cardinal Health

• Medtronic

• C. R. Bard, Inc.

• Johnson & Johnson Services, Inc.

• Spectranetics

• Terumo Medical Corp.

• Tryton Medical Inc.